Zanzalintinib clinical trials
Zanzalintinib is named as an intervention in 16 current clinical trials in our USA, France, UK, Spain, Germany, Poland, Australia, Italy, South Korea, Belgium, Czechia, Brazil, Austria, Mexico, Taiwan, Israel, Netherlands, Singapore, China, Denmark, Turkey, Canada, Ireland, Switzerland and Portugal registers. 10 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Exelixis (11). The most-studied condition is Renal Cell Carcinoma.
How Zanzalintinib works
All drug targets →- Metastatic colorectal cancerPhase 3
- Renal cell carcinomaPhase 3
- Head and neck squamous cell carcinomaPhase 2/3
- Neuroendocrine neoplasmPhase 2/3
- Ewing sarcomaPhase 2
- Bone sarcomaPhase 2
- ChondrosarcomaPhase 2
- Clear cell renal carcinomaPhase 2
- Differentiated thyroid carcinomaPhase 2
- Hepatocellular carcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314428, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12093, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Zanzalintinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Zanzalintinib
16 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Zanzalintinib
28 conditionsAll 28 conditions
| Condition (as registered) | Trials |
|---|---|
| Renal Cell Carcinoma | 3 |
| Renal Cell Carcinoma (RCC) | 2 |
| Solid Tumor | 2 |
| Colorectal Cancer | 2 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Carcinoma, Renal Cell | 1 |
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 1 |
| Urothelial Carcinoma (UC) | 1 |
| Pancreatic Neuroendocrine Tumor (pNET) | 1 |
| Extra-Pancreatic Neuroendocrine Tumor (epNET) | 1 |
| Cancer | 1 |
| Pancreatic Neuroendocrine Tumors (pNET) | 1 |
| Extra-Pancreatic NET (epNET) | 1 |
| Meningioma | 1 |
| Advanced Solid Tumor | 1 |
| Metastatic Solid Tumor | 1 |
| Immune Sensitive Tumor | 1 |
| Hepatic Impairment | 1 |
| Moderate Hepatic Impairment | 1 |
| Adenoid Cystic Carcinoma of the Salivary Gland | 1 |
| Recurrence | 1 |
| Metastatic Disease | 1 |
| Uterine Cancer | 1 |
| Endometrial Cancer | 1 |
| Neoplasm Malignant | 1 |
| Hormone Receptor Positive Breast Carcinoma | 1 |
| Metastatic Castration-resistant Prostate Cancer | 1 |
| Non-Clear Cell Renal Cell Carcinoma | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Exelixis | 11 |
| Merck Sharp & Dohme LLC | 3 |
| UNICANCER | 1 |
| Washington University School of Medicine | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Zanzalintinib trials
How many clinical trials are testing Zanzalintinib?
16 current trials in our USA, France, UK, Spain, Germany, Poland, Australia, Italy, South Korea, Belgium, Czechia, Brazil, Austria, Mexico, Taiwan, Israel, Netherlands, Singapore, China, Denmark, Turkey, Canada, Ireland, Switzerland and Portugal registers name Zanzalintinib (also registered as XL092) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Zanzalintinib trials recruiting patients?
Yes. 10 of the 16 trials are recruiting: 9 with sites in USA, 5 with sites in France, 5 with sites in UK, 5 with sites in Spain, 4 with sites in Germany, 5 with sites in Poland, 4 with sites in Australia, 4 with sites in Italy, 4 with sites in South Korea, 3 with sites in Belgium, 2 with sites in Czechia, 3 with sites in Brazil, 3 with sites in Austria, 3 with sites in Mexico, 2 with sites in Taiwan, 3 with sites in Israel, 2 with sites in Netherlands, 1 with sites in Singapore, 2 with sites in China, 2 with sites in Denmark, 1 with sites in Turkey, 2 with sites in Canada, 1 with sites in Ireland and 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Zanzalintinib clinical trials?
Exelixis (11), Merck Sharp & Dohme LLC (3), UNICANCER (1) and Washington University School of Medicine (1). The number in brackets is how many trials each organisation leads.
Are there Zanzalintinib clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zanzalintinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zanzalintinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zanzalintinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.